Objectives: The Ross procedure is the aortic valve-replacement procedure of choice in children. Nonetheless, late autograft re-operation for dilatation and/or valve regurgitation is of concern. We examined whether preoperative haemodynamic manifestation (e.g., stenosis, regurgitation and mixed aortic valve disease) affected late re-operation risk. Methods: Medical records of 227 children who underwent the Ross procedure (1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004) were reviewed. Competing-risks methodology determined time-related prevalence and associated factors for two mutually exclusive end-states after the Ross procedure: (1) death prior to subsequent autograft re-operation and (2) autograft re-operation, with the remainder of patients being alive and free from subsequent autograft re-operation. Results: There were 162 male patients (71%) in this study. Median age at surgery was 12.1 years (range: 1 week-18 years). The haemodynamic aortic valve dysfunction was primarily stenosis (n = 40, 18%), primarily regurgitation (n = 109, 48%) and mixed disease (n = 78, 35%). Underlying pathology was rheumatic fever (n = 104, 46%), congenital heart disease (n = 113, 50%) and endocarditis (n = 8, 3%). Competing-risks analysis showed that, at 10 years following the Ross procedure, $5% of patients had died, 16% had undergone autograft re-operation with aortic valve replacement and 79% were alive and free from autograft reoperation. Ten-year freedom from autograft re-operation for patients with preoperative stenosis, regurgitation and mixed disease was 97%, 69% and 93%, respectively, ( p < 0.001 for regurgitation vs others). Risk factors for increased risk of autograft re-operation were rheumatic fever (parameter estimates (PEs): 2.09 AE 0.75, p = 0.006), and earlier year of surgery (PE: 0.20 AE 0.06, p = 0.001). Ten-year freedom from homograft replacement was 81% and was not dependent on haemodynamic manifestation (PE: À0.16 AE 0.38, p = 0.68). Significant factors for homograft replacement included fresh homografts (PE: 2.2 AE 0.63, p = 0.01) and annular enlargement (PE: 1.11 AE 0.3, p = 0.01). Ten-year freedom from cardiac re-operation other than auto-/homograft was 85%, higher in patients with preoperative aortic regurgitation (PE: 1.01 AE 0.42, p = 0.02). Concomitant cardiac surgery was a significant factor for late cardiac re-operation other than auto-/homograft replacement (PE: 1.79 AE 0.39, p < 0.001). Conclusions: The Ross procedure in children is associated with excellent survival. Late autograft re-operation may be required; however, it is more common in children with preoperative aortic regurgitation, especially those with rheumatic fever. Better patient selection in later era has mitigated the risk of autograft re-operation. Continued improved candidate selection, along with modifications in autograft implantation and root/sinotubular stabilisation techniques, may further decrease late autograft failure. #
Introduction
Aortic valve disease is common in children and frequently requires intervention. Congenital aortic valve disease is the most common pathology in North America and is encountered in $5% of children with congenital heart disease [1] . While the incidence of rheumatic valve disease has significantly decreased in the Western world, it remains a major cause of aortic valvulopathy in developing countries [2] . Several developments in interventional cardiology allowed early treatment of congenital aortic stenosis, while recent experience with aortic valve-repair techniques shows encouraging short-and mid-term results in both congenital and rheumatic valve disease [3, 4] . Nonetheless, in patients with significant valve destruction and following repair or intervention failure, aortic valve replacement is required.
The Ross procedure is considered by many as the aortic valve replacement of choice in children and young adults as it is associated with excellent haemodynamics and cardiac recovery, it offers growth potential and does not require long-term anticoagulation [5] [6] [7] [8] [9] [10] [11] [12] [13] . Nonetheless, the procedure is technically demanding and the incidence of late autograft failure, aortic root dilatation and homograft reoperations are concerning despite excellent long-term survival [14] [15] [16] [17] .
Several risk factors for autograft failure were identified, such as underlying rheumatic fever, bicuspid aortic valve disease, geometric mismatch between the two semilunar valves and pure preoperative aortic valve regurgitation, suggesting that a more careful patient selection may improve long-term autograft longevity [2, [15] [16] [17] .
In the current report, we aim to examine time-related freedom from re-operation following the Ross procedure in children and assess whether preoperative haemodynamic manifestation of aortic valve disease is associated with an increased risk of late autograft failure and subsequent aortic valve replacement. Ultimately, the goal is to improve patient selection and identify the best candidates to receive the Ross procedure among children requiring aortic valve replacement.
Patients and methods

Inclusion criteria
From 1991 to 2004, 227 consecutive children younger than 18 years of age underwent aortic valve replacement using the Ross procedure at the King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia. Patients were identified using the hospital surgical database. Clinical, operative and outcome data were abstracted from their medical records. Approval of this study was obtained from the Research Ethics Board at our institution and requirement for individual consent was waived for this observational study.
Operative details
Midline sternotomy was performed and standard cardiopulmonary bypass and myocardial protection techniques were used in all cases. The pulmonary autograft was implanted as a full root with coronary transfer in all cases. The autograft muscle-cuff was trimmed with sutures placed almost directly at the base of the cusps. The proximal suture line was performed using running polypropelene sutures. The proximal suture line was reinforced with a strip of a felt in 31 (14%) older patients with dilated annulus. In 32 patients (14%) with narrow left ventricular outflow tract (LVOT), a modified Ross-Konno technique was used. In those patients, the fibrous annulus of the aortic valve was often divided, and the cut was partially taken down to the septum. Part of the septum was cored out to completely open up the LVOT without creating a ventricular septal defect (VSD). The distal suture line was occasionally reinforced with Teflon felt in patients with a dilated ascending aorta (n = 8).
Right ventricle to pulmonary artery (RV-PA) continuity was established with a homograft in all patients. The median homograft size used for reconstruction of the right ventricular outflow tract was 22 mm (range: 17-29). Fresh homografts were used in 50% of cases; cryopreserved homografts were used in the other half. Pulmonary homografts were used in 82% of cases, while aortic homografts were used in 18%. Homografts were not generally matched for the blood group of the patients.
Fifty-eight patients (26%) required concomitant cardiac surgery including mitral valve repair (n = 45), pulmonary artery augmentation (n = 2), resection of ascending aortic aneurysm (n = 2), VSD closure (n = 2), coronary artery bypass grafting (n = 1), sub-aortic membrane resection (n = 1) and aortic arch reconstruction (n = 1).
The immediate postoperative results were assessed in all patients in the operating room by means of trans-oesophageal echocardiography.
Follow-up
Patients were evaluated clinically and by means of detailed echocardiography upon discharge, 6 weeks after the operation, at 6 months and yearly thereafter.
Late outcomes were determined from recent office visits at the King Faisal Specialist Hospital and Research Center or from direct correspondence with patients' families. Followup was complete in 90% of patients, partial in 7% while an additional eight patients (4%) were lost to follow-up. The median follow-up duration was 7.8 years and ranged up to 18.5 years.
Statistical analysis
Data are presented as mean with standard deviation (SD), median with minimum and maximum values and frequencies as appropriate. Comparisons among pathological groups were performed using three-way analysis of variance (ANOVA) and chi-square tests. Time-dependent outcomes (death and reoperation) after the Ross procedure were parametrically modelled. Parametric probability estimates for time-dependent outcomes use models based on multiple, overlapping phases of risk (available for use with the Statistical Analysis Software (SAS) system at http://www.clevelandclinic.org/ heartcenter/hazard). The HAZARD procedure uses maximum likelihood estimates to resolve risk distribution of time to event in up to three phases of risk (early, constant and late). Competing-risks analysis was performed to model the probability over time to occurrence of two mutually exclusive end points: autograft re-operation and death without autograft re-operation; the remainder of patients being alive and free from autograft re-operation. In addition, parametric survival models were created for the following end points: homograft re-operation, cardiac re-operation other than autograft and homograft re-operation and freedom from more than mild aortic regurgitation. Variables potentially influencing the likelihood of outcomes in the competing-risks models were sought in a stepwise multivariate regression model ( p < 0.05 to enter) to obtain the final model for each outcome. Effects of covariates on the probability of outcomes in competing-risks models are given as parameter estimates (change in hazard associated with change of 1 unit in the independent variable; positive estimates associated with increased risk; negative estimates with decreased risk) and percent reliability in the bootstrap algorithm. Clinical relevance of identified covariates on likelihood of selected outcomes was established by solving the regression equations for multiple 'typical' test patients.
All statistical analyses were performed using the SAS statistical software v9.1 (The SAS Institute, Cary, NC, USA).
Results
Patient characteristics
There were 162 male patients (71%). Median age at the Ross procedure was 12.1 years (range: 1 week-18 years). The haemodynamic aortic valve dysfunction was primarily stenosis in 40 patients (18%), primarily regurgitation in 109 patients (48%), and mixed in 78 patients (35%).
The underlying pathology was rheumatic fever in 104 (46%), congenital in 113 (50%) endocarditis in eight (3%) in addition to other pathologies in two patients (1%).
Patients primarily presenting with regurgitation were operated on relatively earlier in our experience, were older and had a higher incidence of rheumatic fever than those with stenosis or mixed aortic valve disease (Table 1) .
Competing-risks analysis for death or subsequent aortic valve replacement after the Ross procedure
Following the 227 initial Ross procedures, 29 patients (13%) had their autografts subsequently replaced and nine patients (4%) died without a further re-operation, the majority (n = 7) being operative mortalities. A 10th patient died 15 months after a subsequent aortic valve replacement.
The hazard function for time-related transition to autograft re-operation was characterised by the presence of a late hazard phase that peaks $2-4 years postoperatively but persisted as years since surgery progressed (Fig. 1A  and B) . The hazard function for time-related transition to death without autograft re-operation was characterised by a small early hazard phase in the immediate postoperative period but stable survival thereafter. The competing risks for the two events showed that, at 10 years following the Ross procedure, $5% of patients have died, 16% have undergone autograft re-operation with aortic valve replacement and 79% were alive and free from autograft re-operation ( Fig. 2 ).
Factors associated with mortality
At last follow-up, there were a total of 10 deaths including seven operative (3%) and three late deaths. One of the late deaths was of a patient in whom the autograft was replaced by a mechanical valve and he had mechanical valve-related mortality.
Factors associated with higher risk of death after the Ross procedure were sought and results are shown in Table 2 . Smaller homograft size, a proxy for younger age, was a significant risk factor for mortality (parameter estimate (PE): +0.32 (0.09), p = 0.001). Preoperative stenosis was a risk factor on univariate analysis but not on multivariable analysis (Table 2 ).
Factors associated with subsequent aortic valve replacement
During follow-up, there were 29 autograft re-operations (13%). All autograft re-operations were due to the development of aortic regurgitation. The predominant pathology causing regurgitation was annular dilatation with cusp prolapse and failure of co-aptation (n = 18), recurrence of inflammatory valvulopathy similar to that in rheumatic fever Fig. 2 . Competing-risks depiction of outcomes following the Ross procedure in children 1-18 years of age. The competing risks for the 2 events (autograft reoperation and death without autograft re-operation) showed that at 10 years following the Ross procedure, approximately 3% of patients have died, 17% have undergone autograft re-operation with aortic valve replacement and 80% were alive and free from autograft re-operation. (n = 8), unknown (n = 2) and endocarditis (n = 1). All autograft re-operations required aortic valve replacement with a mechanical prosthesis. Parametric freedom from autograft re-operation was 99%, 88% and 82% at 1, 5 and 15 years, respectively. There were no differences between parametric and non-parametric freedom from aortic valve replacement. Ten-year freedom from autograft re-operation for patients with preoperative stenosis, regurgitation and mixed aortic valve disease was 96%, 71% and 97%, respectively, ( p < 0.001 for regurgitation vs other) (Fig. 3 ).
Factors associated with higher risk of autograft reoperation after the Ross procedure were sought and results are shown in Table 2 . Significant factors for late-phase reoperation were rheumatic fever (PE: +2.09 (0.75), p = 0.006) and earlier year of surgery (PE: +0.20 (0.06), p = 0.001).
The higher risk of autograft re-operation and subsequent aortic valve replacement following the Ross operation in children with underlying rheumatic fever aetiology are depicted in Fig. 4A while the increased risk for autograft re-operation in patients who underwent the Ross procedure at an earlier era is shown in Fig. 4B. Fig. 5 portrays the riskadjusted freedom from subsequent aortic valve replacement adjusted for the high-risk patient with a combination of unfavourable factors versus the low-risk patient who does not have those risk factors.
Factors associated with autograft regurgitation
A review of follow-up echocardiograms was performed. Overall freedom from more than mild aortic regurgitation was 99%, 85% and 49% at 1, 5 and 15 years, respectively. The 15-year freedom from more than mild aortic incompetence (AI) was 90% in patients with preoperative stenosis versus 41% in those with pure preoperative regurgitation (PE: +1.14 (0.32), p = 0.001). Freedom from more than mild AI at 15 years was 35% for patients with underlying rheumatic pathology versus 81% for those with other pathologies (majority being congenital).
Factors associated with higher risk of development of more than mild AI after the Ross procedure were sought and results are shown in Table 2 . Significant factors for development of more than mild AI were rheumatic fever (PE: +0.70 (0.30), p = 0.02) and concomitant cardiac surgery (PE: +0.79 (0.28), p = 0.005). Fig. 3 . Parametric model for freedom from autograft re-operation and subsequent aortic valve replacement after the Ross procedure stratified by preoperative haemodynamic manifestation of aortic valve disease: stenosis, mixed and regurgitation ( p = 0.001). The models for stenosis and mixed disease were identical and overlapped so they are depicted as a single curve. 
Factors associated with RV-PA homograft replacement
During follow-up, 29 patients (13%) underwent RV-PA homograft re-operations. Overall freedom from homograft re-operation was 99%, 93% and 74% at 1, 5 and 15 years, respectively. Homograft replacement was not different between patients with preoperative stenosis, regurgitation or mixed aortic valve disease (PE: À0.16 (0.38), p = 0.68).
Factors associated with higher risk of homograft replacement after the Ross procedure were sought and results are shown in Table 2 . Significant factors for homograft reoperation were the use of fresh homografts (PE: +2.22 (0.63), p = 0.01), annular enlargement (PE: +1.11 (0.43), p = 0.01) and later year of surgery (PE: +0.20 (0.08), p = 0.01).
Factors associated with cardiac re-operation other than autograft or homograft replacement
During follow-up, 28 patients (12%) underwent additional cardiac re-operations other than autograft or RV-PA homograft replacement. Those procedures were done either independently or simultaneous to auto-/homograft replacement. Overall freedom from those additional cardiac reoperations was 97%, 87% and 85% at 1, 5 and 15 years, respectively. More number of patients with preoperative aortic valve regurgitation eventually underwent additional cardiac re-operations (20/109, 18%) compared to those with stenosis (5/40, 13%) or mixed disease (3/78, 4%), p = 0.02. The majority of these re-operations involved the mitral valve (repair or replacement) in addition to a few cases of pulmonary artery reconstruction or tricuspid valve repair.
Factors associated with higher risk of cardiac re-operation other than auto-or homograft replacement after the Ross procedure were sought and results are shown in Table 2 . The only significant factor for those re-operations was concomitant cardiac operation at the time of the Ross procedure (PE: +1.79 (0.39), p < 0.001) (Fig. 6) .
Overall freedom from all-cause cardiac re-operation was 95%, 81% and 56% at 1, 5 and 15 years, respectively, and was obviously lower in patients with preoperative aortic regurgitation compared to other groups (PE: +0.69 (0.30), p = 0.03), mainly due to the higher autograft-re-operation risk in those patients.
Discussion
Our study reports a single institution's experience with aortic valve replacement using the Ross procedure in 227 children younger than 18 years of age. Competing-risks analysis was chosen because these patients were simultaneously at risk for two most important mutually exclusive events: death and autograft re-operation. Conventional time-related analyses consider individual events such as death or re-operation either in isolation or as a combined end point. Although useful, they do not address the question of how often an event may occur in the absence of other events for which a patient is at simultaneous risk.
Survival
Despite surgical complexity, the Ross procedure is safe in experienced hands [5] [6] [7] [8] [9] [10] [11] [12] [13] . In the current study, operative mortality was 3%, similar to that from The International Registry for the Ross Procedure (2.5%). Small homograft size was identified as a risk factor for death in our current series. This is likely due to the fact that a small homograft is a marker for younger patients with congenital heart disease, both aspects considered relative risk factors for early mortality in previous reports [6] . Of note, all operative mortalities in our series were in children with congenital heart disease while it was zero in children with rheumatic fever, despite the higher requirement of concomitant mitral surgery patients with rheumatic fever.
Most importantly, survival following the Ross procedure was stable with only two late deaths, one of them related to complications of a mechanical valve in a patient who required autograft re-operation and replacement with a mechanical prosthesis. This very low late mortality compares favourably with mechanical prostheses that are associated with continuous attrition with time due to thrombo-embolic/ haemorrhagic complications in children in whom proper anticoagulation is difficult to attain [8] .
Autograft re-operation
Despite excellent survival and superior haemodynamics following the Ross procedure, the recommendation for this procedure has been declining, especially in older patients in whom there are other alternatives. This is mainly due to concerns about the development of aortic root dilatation, with or without the subsequent autograft regurgitation [14] [15] [16] [17] .
Patients with bicuspid aortic valves (BAVs) and dilated ascending aortas, those primarily with aortic regurgitation, dilated aortic roots and geometric mismatch between the two semilunar valves, especially those with rheumatic fever, have been considered the highest risk groups for autograft dilatation and neo-aortic regurgitation in some series [14] [15] [16] [17] . Preoperative aortic regurgitation and geometric mismatch between the aortic annulus and the pulmonary valve diameter have been reported, in several series, to be associated with autograft failure. Laudito et al. described a series of 72 Ross procedures in children. Autograft reoperation was necessary in the follow-up period in seven patients for severe aortic regurgitation. The presence of predominant preoperative aortic regurgitation was a risk factor for autograft failure [15] . Similarly, Elkins et al. showed that children with a diagnosis of aortic regurgitation were at increased risk for autograft reintervention following the Ross procedure [7] . The pathophysiology is likely because aortic regurgitation is usually associated with annular and aortic root dilatation. When the root is replaced by an autograft, the valve commissures are splayed open which, in addition to the dilated annulus, contributes to poor central co-aptation and subsequent regurgitation [16, 18] .
Rheumatic fever was also identified as a risk factor for autograft failure. This association between autograft reoperation and rheumatic fever has been highlighted previously in reports from our institution [3] . Modes of failure at our centre were mainly aortic root dilatation and cusp prolapse in 46%, recurrent rheumatic activity in 25%, inflammatory process that was likely recurrent rheumatic disease in 18%, aneurysm formation without regurgitation in 7% and endocarditis in 4% of failures. We have previously identified risk factors for autograft failure and those included active rheumatic heart disease, concomitant severe rheumatic mitral regurgitation, predominant aortic regurgitation with severe dilatation of the aortic annulus >29 mm or discrepancy between aortic annulus and pulmonary valve >2-3 mm in favour of the aortic annulus [3] . Since the beginning of 1999, we created a new selection criteria, avoided patients with above-listed risk factors and adapted surgical modifications such as careful trimming of the muscle rim under the autograft and suturing close to the base of the cusps, as this muscle rim may dilate and contribute to future failure, with occasional reinforcement of the dilated sinotubular junction. Our current results indicate that the incidence of autograft failure and subsequent aortic valve replacement has been alleviated following the adaptation of those changes. Despite a relatively shorter follow-up, this finding is encouraging considering that most failures were previously evident in the first 2-4 years following surgery.
All patients in our series received the full root autograftimplantation technique. Recent literature suggests that alternative implantation strategies, such as the subcoronary or miniroot inclusion techniques, may be associated with a lower incidence of autograft failure and may be considered in patients at high risk for root dilatation and autograft failure [19] [20] [21] . Alternatively, annular reduction and stabilisation techniques have shown some reduction in autograft failure rates in adults; however, they were not commonly used in the paediatric population [19] [20] [21] . While our analysis did not identify annular stabilisation as a protective factor for autograft failure, this may be due to the small sample size in our series.
Of note, several authors described surgical modifications to prevent autograft dilatation. Moritz et al. reduced the diameter of the aortic annulus and wrapped the pulmonary autograft with an absorbable mesh [22] . Pacifico et al. described an operative technique wherein the entire pulmonary autograft was wrapped with glutaraldehyde-fixed bovine pericardium to prevent dilation [23] . Most recently, Slater et al. described a modification in which the pulmonary autograft was encased in a Dacron tube to prevent dilatation [24] . These techniques are suitable only for patients who will not need growth of the autograft because the outer shell prohibits this. Further follow-up is required to confirm the hypothetical advantages of those modifications. Meanwhile, we have not used any of those modifications at our centre.
One final notable advance is the progress in valvepreserving root-replacement techniques. Those techniques have been successfully used following the Ross procedure in patients with root dilatation and autograft regurgitation and may increase valve longevity despite aortic wall reintervention [25] .
Study limitations
This case series is subject to the limitations inherent in all retrospective observational studies, such as selection bias and lack of randomisation. In addition, the multiple variables in this series that reflect changes in selection criteria and development of different surgical modifications all preclude sophisticated statistical analyses and limit the power of the study to identify clinically significant risk factors. Moreover, the study cohort includes patients with different underlying pathologies; while the mode of failure in patients with rheumatic valve disease is relatively early and, therefore, our follow-up is adequate in this sub-group of patients; the mode of failure in patients with congenital aortic valve disease is more progressive and relatively late and, therefore, longer follow-up may be required for proper assessment of this sub-group of patients. Finally, our series lacks a retrospective assessment of aortic dimensions, LV size and function, aortic regurgitation and outflow gradients in serial echocardiographic examinations by an independent cardiologist and, therefore, the pattern of progression of all those parameters is not well described in this report.
Conclusion
The Ross procedure in children is associated with excellent survival. Nonetheless, late autograft failure due to aortic regurgitation, with or without dilatation of the root and sinotubular junction, is a major concern. Patients with predominant preoperative aortic regurgitation, especially those with associated risk factors such as rheumatic fever and concomitant mitral regurgitation, are at higher risk of autograft failure. Better patient selection by avoiding those with predominant regurgitation, dilated aortic root and annulus and significant geometric mismatch between the two semilunar valves have resulted in a substantial decrease in the rate of autograft failure and re-operation. Surgical modifications aiming at limiting autograft dilatation can be used in older patients and may further mitigate late autograft failure risk; however, longer follow-up is required to confirm these theoretical advantages.
Appendix A. Conference discussion Dr A.E. Wood (Dublin, Ireland): I think to describe an ideal operation would be an operation that has a low operative mortality of zero, very few, if any, complications or side effects, and a very effective long-term outcome with no requirement for re-operation. Now, the Ross procedure has been stated repeatedly, and again today, to be the ideal operation for the very young. I note in your particular group that the majority of the people that you're operating on are between 10 and 15 years of age.
Importantly, you had an autograft re-operation in 14%, 29 patients, predominantly those presenting with pure regurgitation. I note that 36% of the regurgitation patients were reoperated on at 10 years, and your median follow-up period for the whole series is 7.8 years.
Importantly you've also stated the re-operation rate for right ventricular outflow tract problems, and this is important as the Ross procedure actually changes patients from single valve disease to double valve disease. And I note that 28 patients underwent re-operation on the right side. That's 13.6%. But more importantly, at 15 years of follow-up on your longitudinal studies, you've demonstrated that I think it is 24% would come up to operation.
When you take your whole series together, this means that during the median period of follow-up of just under 8 years, just over 40% of your patient cohort have required some re-operation.
My questions are as follows: Do you still think that the Ross operation is the operation of choice in particular for those patients with aortic incompetence aged between 10 years and 18 years of age?
At operation, did you note any geometric mismatch between the recipient aortic annulus and the pulmonary autograft? This is not mentioned in the paper.
And lastly, what now would your criteria be to use the Ross operation? Dr Alsoufi: One of the limitations of this study is that we didn't examine the effect of any echocardiographic parameters, besides the preoperative haemodynamic manifestation, on end outcomes.
As I demonstrated in one of the slides, the surgical era was associated with an increased risk of autograft re-operation. Before 1999, the Ross procedure was offered to almost all children at our institution, regardless of the diagnosis, geometric mismatch, or haemodynamic manifestation. However, we noted that there was a high autograft re-operation rate and several risk factors for re-operation were identified.
Starting in 1999, we adopted changes in our selection criteria and surgical technique. One of those changes was not to offer the Ross procedure to patients with geometric discrepancy between the two semilunar valves. So we don't currently offer the Ross procedure to patients in whom the pulmonary valve is about 2 to 3 mm smaller than the aortic annulus, or in adult patients, our cutoff is an aortic valve annulus that is 29 or 30 mm in diameter.
So who do we offer the Ross procedure to right now? We offer it to children with congenital aortic valve disease almost uniformly, except for the rare young teenagers with bicuspid aortic valve, pure regurgitation and dilated aortic annulus. We also continue to offer the Ross procedure to patients with rheumatic aortic valve disease if they don't have the associated risk factors such as concomitant severe MR, active rheumatic disease, pure aortic regurgitation with significant geometric discrepancy between the semilunar valves. By adhering to those selection criteria, we demonstrated that the risk of early autgraft failure is much lower in the later era after 1999.
We still believe that the Ross procedure, at least in our part of the world, is a better replacement choice. In a previous study from our institution that we presented at AATS two years ago, we performed a propensity score comparison between children who underwent aortic valve replacement with either the Ross procedure or a mechanical prosthesis. In that study, we found an important survival advantage for the Ross procedure compared to mechanical valves.
Dr J. Fragata (Lisbon, Portugal): I have some questions. I would like to hear your opinion on a group I am particularly interested in -the rheumatic fever patients. I was always ever reluctant to offer the Ross procedure to these children.
The question is, when you reoperate those patients, what do you find in the autograft? Are they the same characteristics as an aortic valve with rheumatic disease which shrinks calcification of the leaflets? And how safe is it to offer the operation to the aortic regurgitation in a child with stabilized rheumatic fever?
Dr Alsoufi: In a previous publication from our institution, my colleague Dr Al-Halees was one of the first surgeons to point out failure problems of the Ross procedure in patients with rheumatic fever.
In those rheumatic patients who required autograft re-operation, about 50% of the failures were due to annular dilatation, aneurysm formation or cusp prolapse. However, the other 50% of failures were due to recurrence of rheumatic valve disease or nonspecific inflammatory process that was likely rheumatic, in addition to a few cases of endocarditis.
Dr Fragata: So the last one is when you should not use it? Dr Alsoufi: Again, we've identified several risk factors and we changed our selection criteria in patients with rheumatic valve disease. In the current series, we're showing that by adopting those changes in our selection criteria that we pointed out about 10 years ago, the risk of autograft re-operation in children with rheumatic aortic valve disease can be much lower.
Our follow-up is shorter in children who had surgery in the later era of the study. However, as I showed earlier, most of the autograft failures in the rheumatic population were within 2 to 3 years following the Ross procedure; so we've already passed this high-risk period successfully, and that may predict that we will continue to show a more favourable re-operation rate with longer follow-up.
Dr J. Brown (Indianapolis, Indiana): Very impressive series, but I would like to address the geometric mismatch.
At our institution, we have not denied patients with a geometric mismatch a Ross procedure because we think we can successfully reduce the dilated aortic annulus down to the size of the autograft and have been able to stabilise it with prosthetic material.
And it would appear that if you stabilize not only the annulus that is dilated and the sinotubular junction and replace the ascending aorta, if it's dilated, in an older child (you obviously can't do this in a small child), that the results seem to be comparable to what we can achieve in the standard Ross patient without any mismatch.
Why have you gone away from the geometric mismatch, and why is not annular reduction still offered in your practice?
Dr Alsoufi: Although we've rarely performed annular reduction in the current patient cohort; annular reduction in adult patients with rheumatic valve disease, regurgitation and annular dilatation was attempted at our institution without an improvement in reoperation risk. This discrepancy between our institution and yours may be due to the different patient population with significantly more children with underlying rheumatic valve disease at our institution.
One surgical technique modification that we've adopted was to trim the muscle rim underneath the autograft cusps almost completely with sutures going directly to the base of the cusp. We believe that this modification decreases the risk of aneurysm formation and later development of AI.
As you stated, in older children in whom future growth limitation is not a major concern; annular and root stabilization techniques may play an important role in further mitigating the risk of autograft failure and subsequent reoperation.
